Selecta Biosciences to Participate in Jefferies Virtual Gene Therapy/Editing Summit

October 20, 2021

WATERTOWN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Gene Therapy/Editing Summit to be held October 27-28, 2021.

Details on the conference can be found below.

**Jefferies Virtual Gene Therapy/Editing Summit**
- **Format:** Presentation and one-on-one investor meetings
- **Date:** Wednesday October 27, 2021
- **Presentation Time:** 11:00 a.m. EST
- **Webcast:** [Click Here](#)

An archived webcast will also be accessible in the Investors & Media section of the company’s website at [www.selectabio.com](http://www.selectabio.com).

**About Selecta Biosciences, Inc.**
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit [www.selectabio.com](http://www.selectabio.com).

**For Investors:**
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com

**For Media:**
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com

Source: Selecta Biosciences, Inc.